Pacira Pharmaceuticals (NASDAQ:PCRX) reported earnings of $0.24 per share beating Walls Streets expectations.

ME Staff
-
0

Pacira Pharmaceuticals (NASDAQ:PCRX) reported Q2 2018 earnings this Morning, coming in at $0.24 per share, beating Wall Street’s estimates of $0.05 per Share. Revenue for the quarter came in at $84.10 million beating analyst estimates of $77.53 million

Recent Insider Trading for Pacira Pharmaceuticals (NASDAQ:PCRX)

  • On 6/7/2018 David M Stack, CEO, sold 18,406 with an average share price of $36.28 per share and the total transaction amounting to $667,769.68.
  • On 6/4/2018 Charles A Reinhart III, CFO, sold 708 with an average share price of $33.02 per share and the total transaction amounting to $23,378.16.
  • On 6/4/2018 Kristen Marie Williams, CAO, sold 2,040 with an average share price of $33.02 per share and the total transaction amounting to $67,360.80.
  • On 6/4/2018 Lauren Bullaro Riker, VP, sold 801 with an average share price of $33.02 per share and the total transaction amounting to $26,449.02.
  • On 6/4/2018 Paul J Hastings, Director, sold 771 with an average share price of $33.90 per share and the total transaction amounting to $26,136.90.
  • On 6/4/2018 Richard Scranton, Insider, sold 1,367 with an average share price of $33.02 per share and the total transaction amounting to $45,138.34.



    About Company
    Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

    Recent Analyst Rating for Pacira Pharmaceuticals (NASDAQ:PCRX)



      Recent Trading for Pacira Pharmaceuticals (NASDAQ:PCRX)
      Shares of Pacira Pharmaceuticals closed the previous trading session at with shares trading hands.